Nuvation Bio, based in San Francisco, develops novel oncology therapies and has 159 employees. Its clinical portfolio includes candidates like taletrectinib and safusidenib, targeting specific cancer mutations.
Philippe Sauvage bought 3,300 shares of NUVB on 16 June at $1.83 per share, worth a total of $6K. They now own 5,902 NUVB shares, or a 127% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.